Senaste uppdateringen :
19/11/2024
Andningsstimulerande medel   Caffeine citrate  
injektion
Oral lösning
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Cafcit Förenta Staterna
Cafeina 25% Bioquim Argentina
Cafeina citrato Spanien
Cafeina Fada Argentina
Cafeine citrate Biomed nya Zeeland
Cafeine Sterop Belgien
Cafeinnova Colombia
Caffeinospire Egypten
Cafirate Indien
Citrate de caféine Cooper Frankrike
Peyona oral y para perfusion Spanien
Peyona oral/parenteral Rumänien, Turkiet, Tyskland
Hänvisningar   injektion   Hänvisningar : Caffeine citrate  
Typ Publikation
43 tidningen Fraser BD, Berod T, Whitney HAK.
Stability of caffeine citrate injection in polypropylene syringes at room temperature.
Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318 tidningen Donnelly RF, Tirona RG.
Stability of citrated caffeine injectable solution in glass vials.
Am J Hosp Pharm 1994 ; 51: 512-514.
691 tidningen Nahata MC, Zingarelli JR, Durell DE.
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions.
J Clin Pharm Ther 1989 ; 14: 53-55.
1802 tidningen Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087 tidningen Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
3379 tidningen Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3644 Laboratorium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3976 tidningen Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319 tidningen Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 tidningen Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4419 tidningen Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543 tidningen Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 tidningen Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 tidningen Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4837 tidningen De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales